{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:56:39Z","timestamp":1791309399305,"version":"4.3.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jhep.2026.01.009","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:18:02Z","timestamp":1769213882000},"page":"1178-1182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Revisiting prophylactic corticosteroids to mitigate severe immune-related adverse events in hepatocellular carcinoma"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8426-9071","authenticated-orcid":false,"given":"Ying-Chun","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8891-4426","authenticated-orcid":false,"given":"Tsung-Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8975-9491","authenticated-orcid":false,"given":"Li-Chun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2327-0340","authenticated-orcid":false,"given":"Chien-Huai","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6367-8977","authenticated-orcid":false,"given":"Po-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7334-1912","authenticated-orcid":false,"given":"Yu-Yun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0349-9180","authenticated-orcid":false,"given":"Zhong-Zhe","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9152-6512","authenticated-orcid":false,"given":"Ann-Lii","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2026.01.009_bib1","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1158\/1078-0432.CCR-12-3243","article-title":"Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma","volume":"19","author":"Feng","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2026.01.009_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2026.01.009_bib3","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II Study","volume":"39","author":"Kelley","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.01.009_bib4","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2026.01.009_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhep.2026.01.009_bib6","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.01.009_bib7","doi-asserted-by":"crossref","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN Guidelines\u00ae Insights: management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jhep.2026.01.009_bib8","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s12016-022-08932-2","article-title":"Premedication protocols to prevent hypersensitivity reactions to chemotherapy: a literature review","volume":"62","author":"F","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jhep.2026.01.009_bib9","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.01.009_bib10","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.01.009_bib11","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2026.01.009_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111138","article-title":"Impact of prophylactic dexamethasone on the efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy in patients with advanced non-squamous non-small-cell lung cancer","volume":"125","author":"Yu","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jhep.2026.01.009_bib13","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000534350","article-title":"Effects of early short-course corticosteroids on immune-related adverse events in non-small cell lung cancer patients receiving immune checkpoint inhibitors","volume":"102","author":"Huang","year":"2024","journal-title":"Oncology"},{"key":"10.1016\/j.jhep.2026.01.009_bib14","first-page":"93","article-title":"Effect of pretreatment with dexamethasone on the efficacy and immune-related adverse events of immunotherapy in first-line treatment for advanced non-small cell lung cancer: a network meta-analysis of randomized control trials","volume":"10","author":"Li","year":"2021","journal-title":"Am J Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.jhep.2026.01.009_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009704","article-title":"Corticosteroid premedication on anti-tumor effect of immune checkpoint blockade in murine hepatocellular carcinoma models","volume":"13","author":"Shen","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.jhep.2026.01.009_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000726","article-title":"Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy","volume":"8","author":"Pinato","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhep.2026.01.009_bib17","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1084\/jem.20190738","article-title":"Selective inhibition of low-affinity memory CD8(+) T cells by corticosteroids","volume":"216","author":"Tokunaga","year":"2019","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhep.2026.01.009_bib18","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1066062","article-title":"Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies","volume":"5","author":"Cook","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jhep.2026.01.009_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/archneur.58.1.91","article-title":"High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes","volume":"58","author":"Leussink","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jhep.2026.01.009_bib20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jhep.2026.01.009_bib21","first-page":"119","article-title":"Treatment decision-making in unresectable hepatocellular carcinoma: importance of understanding the different response patterns between IO plus anti-VEGF and IO plus IO regimens","volume":"14","author":"Kudo","year":"2025","journal-title":"Liver Cancer"},{"issue":"Suppl_4","key":"10.1016\/j.jhep.2026.01.009_bib22","doi-asserted-by":"crossref","first-page":"iv100","DOI":"10.1093\/annonc\/mdx216","article-title":"Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines","volume":"28","author":"Rosell\u00f3","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2026.01.009_bib23","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.01.009_bib24","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jhep.2026.01.009_bib25","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/JCO.23.01498","article-title":"Cemiplimab for kidney transplant recipients with advanced cutaneous squamous cell carcinoma","volume":"42","author":"Hanna","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826000218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826000218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:56:49Z","timestamp":1780592209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826000218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0168827826000218"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.01.009","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisiting prophylactic corticosteroids to mitigate severe immune-related adverse events in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}